Last updated: 2026-09-09 04:53:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Sutro Biopharma, Inc. (STRO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $19,14, with a market capitalization of $332,78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7,15 to $43,85. This page covers its latest market performance, valuation, price trends and company information.
$332,78M | |
$19,61 | |
$283,00 | |
$5,23 | |
$20,07 | |
128,91K | |
326,00K | |
-- | |
$43,85 | |
$7,15 | |
-- | |
-- |
Sutro Biopharma, Inc. (STRO) last closed at $20,07 as of 2026-09-09 00:00:00, unchanged from the previous close of $20,07.
During the latest regular trading session, STRO traded between $5,23 and $283,00, with a volume of 128,91K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Sutro Biopharma, Inc. (STRO) moved from $21,31 to $19,14, representing a decline of 10,17% ($2,17).
The stock traded between $19,08 and $21,68 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 136,03 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32,7%
STRO is currently trading at $19,14, placing it 32,7% of the way from its 52-week low of $7,15 to its 52-week high of $43,85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 128 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sutro Biopharma, Inc. (STRO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.